BriaCell Therapeutics Corp Dossier
Qualitative Analysis
Business overview
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company dedicated to developing novel immunotherapies to transform cancer care. The company's proprietary platform focuses on targeted, off-the-shelf, cell-based immunotherapies designed to activate the patient's immune system to destroy cancer cells selectively. Its lead clinical candidate, Bria-IMT™, is a genetically engineered human breast cancer cell line with features of immune cells. Bria-IMT™ is currently being evaluated in a pivotal Phase 3 clinical trial in combination with the immune checkpoint inhibitor retifanlimab (an anti-PD-1 antibody) for patients with advanced metastatic breast cancer. Additionally, BriaCell is advancing its personalized off-the-shelf platform, Bria-OTS™ (including Bria-BRES™ and Bria-BRES+™), and early-stage programs such as Bria-PROS+™ for prostate cancer and soluble CD80 (sCD80) biologics.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the registrational Phase 3 clinical trial evaluating lead candidate Bria-IMT™ in combination with Incyte's retifanlimab against physician's choice of treatment in advanced metastatic breast cancer.
Expected impact: Potential to establish a new standard of care in metastatic breast cancer and support a BLA submission.
Expanding the personalized off-the-shelf immunotherapy platform to target multiple cancer indications, including breast cancer (Bria-BRES+™), prostate cancer (Bria-PROS+™), and ovarian cancer (Bria-OVA+™).
Expected impact: Broadens the addressable market and validates the off-the-shelf personalized immunotherapy concept across solid tumors.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
BriaCell transferred its exclusive Soluble CD80 (sCD80) license to its majority-owned subsidiary BriaPro in exchange for 23,972,589 BriaPro common shares (valued at approximately C$1.18 million / US$870,000), increasing BriaCell's ownership in BriaPro to approximately 78%. This consolidates small-molecule and biologic immunotherapies under BriaPro.
Financial impact: BriaCell also established a $3.0 million credit facility to fund BriaPro's ongoing research and development efforts.
Strategic Partnerships
Collaboration through MSK's Therapeutics Accelerator Cohort program to accelerate clinical development of the Bria-OTS+™ platform, starting with manufacturing, IND development, and clinical protocol support for a Phase 1 trial of Bria-BRES+™.
Terms: Non-dilutive institutional support, including access to MSK's cell therapy manufacturing and regulatory resources.
Collaboration between BriaCell's subsidiary BriaPro and Receptor.AI to apply AI-driven drug discovery to design highly selective anti-cancer kinase inhibitors, expanding BriaPro's small-molecule oncology pipeline.
Terms: Terms of the collaboration were not publicly disclosed.
Non-exclusive collaboration to evaluate Bria-IMT™ in combination with Incyte's anti-PD-1 checkpoint inhibitor, retifanlimab, in the pivotal Phase 3 BRIA-ABC study.
Terms: Incyte provides retifanlimab for the clinical trial.